Nonalcoholic Fatty Liver Disease in Pediatrics

Duncan, Martin; Zong, Wenjing; Biank, Vincent; Hageman, Joseph R

doi:10.3928/00904481-20160113-01

Cited by 9 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nonalcoholic fatty liver disease (NAFLD) is a generic term for a wide spectrum of disease that ranges from fatty liver to advanced fibrosis and cirrhosis to hepatocellular cancer and end-stage liver failure. A study of childhood and adolescent liver epidemiology showed NAFLD in 9.6% of children between age 2 and 19 years [64]. However, Xanthakos et al [65] evaluated the prevalence of NAFLD in children undergoing MBS in the Teen-LABS population.…”

Section: Obesity Disease-related Co-morbidities and Outcomesmentioning

confidence: 99%

ASMBS pediatric metabolic and bariatric surgery guidelines, 2018

Pratt

Browne

Browne³

et al. 2018

Surgery for Obesity and Related Diseases

415

285

View full text Add to dashboard Cite

The American Society for Metabolic and Bariatric Surgery Pediatric Committee updated their evidence-based guidelines published in 2012, performing a comprehensive literature search (2009-2017) with 1387 articles and other supporting evidence through February 2018. The significant increase in data supporting the use of metabolic and bariatric surgery (MBS) in adolescents since 2012 strengthens these guidelines from prior reports. Obesity is recognized as a disease; treatment of severe obesity requires a life-long multidisciplinary approach with combinations of lifestyle changes, nutrition, medications, and MBS. We recommend using modern definitions of severe obesity in children with the Centers for Disease Control and Prevention age- and sex-matched growth charts defining class II obesity as 120% of the 95th percentile and class III obesity as 140% of the 95th percentile. Adolescents with class II obesity and a co-morbidity (listed in the guidelines), or with class III obesity should be considered for MBS. Adolescents with cognitive disabilities, a history of mental illness or eating disorders that are treated, immature bone growth, or low Tanner stage should not be denied treatment. MBS is safe and effective in adolescents; given the higher risk of adult obesity that develops in childhood, MBS should not be withheld from adolescents when severe co-morbidities, such as depressed health-related quality of life score, type 2 diabetes, obstructive sleep apnea, and nonalcoholic steatohepatitis exist. Early intervention can reduce the risk of persistent obesity as well as end organ damage from long standing co-morbidities.

show abstract

Section: Obesity Disease-related Co-morbidities and Outcomesmentioning

confidence: 99%

ASMBS pediatric metabolic and bariatric surgery guidelines, 2018

Pratt

Browne

Browne³

et al. 2018

Surgery for Obesity and Related Diseases

415

285

View full text Add to dashboard Cite

show abstract

“…Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in children and adolescents in the United States [ 1 – 4 ] with up to 38% of obese children affected [ 5 ]. Prevalence increases with age, reaching approximately 17.5% in adolescents [ 5 ], and with 5 times the risk of fatty liver in Hispanics [ 5 – 7 ].…”

Section: Introductionmentioning

confidence: 99%

Bisphenol a increases risk for presumed non-alcoholic fatty liver disease in Hispanic adolescents in NHANES 2003–2010

et al. 2018

View full text Add to dashboard Cite

BackgroundBisphenol-A (BPA) is a ubiquitous chemical and recognized endocrine disruptor associated with obesity and related disorders. We explored the association between BPA levels and suspected non-alcoholic fatty liver disease (NAFLD).MethodsUnweighted analyses were used to study the relationship between urinary BPA levels and suspected NAFLD (alanine aminotransferase (ALT).> 30 U/L, body mass index (BMI) Z-score > 1.064 and evidence of insulin resistance) using National Health and Nutrition Examination Survey (NHANES) data (2003–2010) on 12–19 year olds. Unweighted and weighted analyses were used to evaluate the risk with only elevated ALT.ResultsWe included 944 adolescents with urinary BPA and fasting laboratory tests from a total of 7168 adolescents. Risk of suspected NAFLD was increased in the second quartile of BPA levels (1.4–2.7 ng/mL) when compared to the first (< 1.4 ng/mL) (Odds Ratio (OR) 4.23, 95% Confidence Interval (CI) 1.44–12.41). The ORs for the third and second quartiles were positive but did not reach statistical significance. The association was stronger in Hispanics (n = 344) with BPA levels in the second (OR 6.12, 95% C.I. 1.62–23.15) quartile and when limiting the analyses to overweight/obese adolescents (n = 332), in the second (OR 5.56, 95% C.I. 1.28–24.06) and fourth BPA quartiles (OR 6.85, 95% C.I. 1.02–46.22) compared to the first quartile. BPA levels were not associated with ALT elevation.ConclusionsThe risk of suspected NAFLD is increased in participants in higher quartiles of BPA exposure, particularly in those of Hispanic ethnicity. Further studies are required to fully understand the potential role of BPA in non-alcoholic fatty liver disease.Electronic supplementary materialThe online version of this article (10.1186/s12940-018-0356-3) contains supplementary material, which is available to authorized users.

show abstract

“…No se encontraron estudios en la literatura que midieran la prevalencia de esteatosis hepática en los pacientes con niveles bajos de vitamina D, en nuestro análisis fue del 13.5%, cifra que si se compara con la prevalencia aislada de EHGNA que va del 3 al 12.6% en la población pediátrica en general ( Uppal 2016, Duncan 2016, Flores 2004 y Clemente 2016) y que aumenta hasta 40-70% en obesos (Duncan 2016), por lo que vale la pena profundizar en la asociación entre estas dos variables.…”

Section: Discussionunclassified

“…Sugerimos implementar un método diagnóstico por imagen con mayor sensibilidad como la elastografía por ultrasonido la cual se encuentra en vías de sumarse a las recomendaciones de las guías internacionales pediátricas (Duncan 2016).…”

Section: Discussionunclassified

Prevalencia de Hígado Graso en Niños con Obesidad y Niveles Bajos de Vitamina D

Valle Leal,

Gamboa Quintero,

López Millán

et al. 2023

Ciencia Latina

View full text Add to dashboard Cite

Introducción: La deficiencia de vitamina D es un problema de salud pública; se ha demostrado puede llegar a intervenir gracias a su receptor VDR en el metabolismo lipídico hepático. El objetivo de este trabajo fue medir la prevalencia de Hígado Graso en pacientes con niveles bajos de Vitamina D. Metodología: Grupo de 68 pacientes ped iátricos, estudio, transversal. Se realizaron mediciones de somatometría, analítica metabólica en ayuno y ultrasonido hepático. Resultados: La prevalencia de enfermedad por hígado graso no alcohólico fue del 8.8% en el total de la muestra y del 13.5% en los que presentaban niveles bajos de vitamina D. Se encontró asociación estadística entre resistencia a la insulina e hígado graso. En el análisis comparativo de medias entre el grupo con hígado graso y sin la enfermedad se obtuvo significancia estadística entre IMC, ICE, HOMA y niveles de insulina. Conclusiones: En nuestro estudio se concluye una prevalencia de EHGNA en los pacientes con deficiencia de Vitamina D del 13.5%. Se muestra una asociación con resistencia a la insulina lo que apoya la necesidad de implementar estrategias dirigidas a abordaje diagnóstico y terapéutico de ambas patologías.

show abstract

Nonalcoholic Fatty Liver Disease in Pediatrics

Cited by 9 publications

References 17 publications

ASMBS pediatric metabolic and bariatric surgery guidelines, 2018

ASMBS pediatric metabolic and bariatric surgery guidelines, 2018

Bisphenol a increases risk for presumed non-alcoholic fatty liver disease in Hispanic adolescents in NHANES 2003–2010

Prevalencia de Hígado Graso en Niños con Obesidad y Niveles Bajos de Vitamina D

Contact Info

Product

Resources

About